

**CCNT1 antibody - N-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI16181**

**Specification**

---

**CCNT1 antibody - N-terminal region - Product Information**

Application	WB
Primary Accession	<a href="#">O60563</a>
Other Accession	<a href="#">NM_001240</a> , <a href="#">NP_001231</a>
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Neisseria Gonorrhoeae, Guinea Pig, Dog
Predicted	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Neisseria Gonorrhoeae, Guinea Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	81kDa KDa

**CCNT1 antibody - N-terminal region - Additional Information**

**Gene ID** 904

**Alias Symbol** CCNT, CYCT1, HIVE1  
**Other Names**  
Cyclin-T1, CycT1, Cyclin-T, CCNT1

**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 50 ul of distilled water. Final anti-CCNT1 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

CCNT1 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**CCNT1 antibody - N-terminal region - Protein Information**

**Name** CCNT1

**Function**

Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which facilitates the transition from abortive to productive elongation by phosphorylating the CTD (C-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II) (PubMed:<a href="http://www.uniprot.org/citations/16109376" target="\_blank">16109376</a>, PubMed:<a href="http://www.uniprot.org/citations/16109377" target="\_blank">16109377</a>)

target="\_blank">16109377</a>, PubMed:<a href="http://www.uniprot.org/citations/30134174" target="\_blank">30134174</a>, PubMed:<a href="http://www.uniprot.org/citations/35393539" target="\_blank">35393539</a>). Required to activate the protein kinase activity of CDK9: acts by mediating formation of liquid-liquid phase separation (LLPS) that enhances binding of P-TEFb to the CTD of RNA Pol II (PubMed:<a href="http://www.uniprot.org/citations/29849146" target="\_blank">29849146</a>, PubMed:<a href="http://www.uniprot.org/citations/35393539" target="\_blank">35393539</a>).

### Cellular Location

Nucleus

### Tissue Location


Ubiquitously expressed.

## CCNT1 antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## CCNT1 antibody - N-terminal region - Images



Host: Rabbit

Target Name: CCNT1

Sample Tissue: HeLa

Antibody Dilution: 1.0µg/ml  
CCNT1 is supported by BioGPS gene expression data to be expressed in HeLa

## CCNT1 antibody - N-terminal region - Background

Regulatory subunit of the cyclin-dependent kinase pair (CDK9/cyclin-T1) complex, also called positive transcription elongation factor B (P-TEFb), which is proposed to facilitate the transition from abortive to productive elongation by phosphorylating the CTD (carboxy-terminal domain) of the large subunit of RNA polymerase II (RNA Pol II). In case of HIV or SIV infections, binds to the transactivation domain of the viral nuclear transcriptional activator, Tat, thereby increasing Tat's affinity for the transactivating response RNA element (TAR RNA). Serves as an essential cofactor for

Tat, by promoting RNA Pol II activation, allowing transcription of viral genes.

### **CCNT1 antibody - N-terminal region - References**

Wei P., et al. Cell 92:451-462(1998).

Peng J.-M., et al. Genes Dev. 12:755-762(1998).

Wu X., et al. Submitted (JUN-2007) to the EMBL/GenBank/DDBJ databases.

Scherer S.E., et al. Nature 440:346-351(2006).

Parada C.A., et al. EMBO J. 18:3688-3701(1999).